1 / 18

Universal Pharmacare: Solving Canada’s Drug Problem

Universal Pharmacare: Solving Canada’s Drug Problem. Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition. Canada’s Drug Problem. 1. No ability to control costs, rising 10.5% a year Drug are overpriced – Canada 3 rd highest in world

walter
Download Presentation

Universal Pharmacare: Solving Canada’s Drug Problem

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Universal Pharmacare:Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition

  2. Canada’s Drug Problem 1. No ability to control costs, rising 10.5% a year • Drug are overpriced – Canada 3rd highest in world • 8 million Canadians uninsured or underinsured • Prescription drug over-use and misuse especially with children and the elderly • New drugs rushed to market based on secret, dubious data. Rx drugs are 4th leading cause of death

  3. Pharma’s 7 Deadly Sins 1. Conducts unethical clinical trials 2. Ghost-writes studies, hides negative results and promotes illegal off-label use to doctors • Bribes doctors, pharmacists and medical researchers • Advertises hazardous drugs with misleading information • Invents illnesses in order to sell more drugs 6. Buys silence from regulators and politicians 7. Prevents the poor from getting medicines

  4. Illegal off-label promotion to MD’s

  5. Big Pharma Profitscompared to Fortune 500 firms (1954-2008; in millions of constant 1984 US$)Source: Fortune

  6. Dominant Business Model:massive promotion of ‘me-too’ drugs & control over Medical Knowledge • Sales: $239.8 billion • R&D: $24.1 billion (10% of revenues) • Promotion: $57.5 billion (24.4% of revenues) • Promotion directed towards physicians: $42.8 billion • Average promotion spending per physician: $61,000 • 1 drug rep for every 6 physicians • Undisclosed promotion: Fellowships, ghostwriting, « off-label », seeding trials, astro-turf groups… Merck made $12.9 billion in 2009 and then closed its research lab in Montreal (180 jobs lost)

  7. Retail price for an identical volume of pharmaceutical products OECD countries, 2005(US$, market exchange rate) Source: OECD 2008 - Eurostat OECD PPP Programme, 2007.

  8. Most New Drugs Have No Significant Advantage Source: France 2001-2010, Préscrire International, 2011

  9. Direct-to-consumer-advertising • Drives up prescription drugs costs • Fails to inform • Compromises public safety: exposure to dangerous drugs before risks are fully recognized, Additionally, most new drugs are costlier than existing treatments, but few provide any therapeutic advantage. • Promotes the medicalisation of normal life

  10. The Economic Case for Universal Pharmacare

  11. Pharmacare Savings - A • Current expenditure on prescription drugs $ 25.141B • Growth in expenditures from increased use +10% • Reduction from decrease in dispensing fees - 2% • Reduction from drug assessment - 8% • Elimination of the monthly deductible in Qc $144M • Elimination of rebate system for generics $1.3B • Elimination of the 15-year rule in Quebec $102M • Change PMPRB price fixing $1.43B • Elimination of extra costs for private plans $560M • Elimination of tax subsidies $933M Total net savings annually $ 4.479B

  12. Pharmacare Savings - B • Savings from competitive purchasing $10.2 B • Growth in expenditures from increase in use +10% Reduction from decrease in dispensing fees -2% • Elimination of the deductible in Qc $ 144M • Elimination of the 15-year rule in Quebec $102M • Elimination of extra costs of private plans $ 560M • Elimination of tax subsidies $ 933M Total savings annually $ 10.744 Billion

  13. Industrial Policies = Total Failure Innovation policies are justified by the multiplying effect on the benefits it creates as compared to costs. With a negative multiplying effect, innovation policies in the pharmaceutical sector are a total failure: • Canada spends $7.4 billion in subsidies • Value-added in return is only $4.8 billion

  14. Rx spending up 73.7%CANADA,1999-2009, per capita, inflation adjusted

  15. Public spending is stable

  16. Universal Pharmacare will save $ billions • Replace our patchwork U.S.-style drug insurance plans with universal, first-dollar coverage (no deductible or co-pay) • Pay only for drugs that have been independently established to be safe and cost-effective • Establish a National formulary • End the price-fixing and public subsidies of Big Pharm • Start bulk purchasing www.PharmacareNow.ca

  17. Pay for What Works

  18. “Democracy is the thing that lets ordinary people do extraordinary things. There isn’t anything we can’t accomplish if we set our minds to it.” - Tommy Douglas Next steps for Canadians

More Related